Delavirdine overdosage: Difference between revisions

Jump to navigation Jump to search
No edit summary
mNo edit summary
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==OVERDOSAGE==
==Overdosage==


Human experience of acute overdose with RESCRIPTOR is limited.
Human experience of acute overdose with RESCRIPTOR is limited.
Line 9: Line 9:
==Management of Overdosage==
==Management of Overdosage==


Treatment of overdosage with RESCRIPTOR should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. There is no specific antidote for overdosage with RESCRIPTOR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Since delavirdine is extensively metabolized by the liver and is highly protein-bound, dialysis is unlikely to result in significant removal of the drug.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher =  | date =  | accessdate =  }}</ref>
Treatment of overdosage with RESCRIPTOR should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. There is no specific antidote for overdosage with RESCRIPTOR. If indicated, elimination of unabsorbed drug should be achieved by [[emesis]] or [[gastric lavage]]. Since delavirdine is extensively metabolized by the liver and is highly protein-bound, [[dialysis]] is unlikely to result in significant removal of the drug.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==

Latest revision as of 04:05, 5 January 2014

Delavirdine
RESCRIPTOR® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

Human experience of acute overdose with RESCRIPTOR is limited.

Management of Overdosage

Treatment of overdosage with RESCRIPTOR should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. There is no specific antidote for overdosage with RESCRIPTOR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Since delavirdine is extensively metabolized by the liver and is highly protein-bound, dialysis is unlikely to result in significant removal of the drug.[1]

References

  1. "RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY]".

Adapted from the FDA Package Insert.